Unveiling HJURP as a Biomarker of Poor Prognosis and Immunotherapy Resistance in Lung Adenocarcinoma: A Multicenter Study
Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.
Authors
- Qinglin Tan (ORCID: https://orcid.org/0000-0002-3924-9837)
- Yanmin Cai
- Jianming Lü (ORCID: https://orcid.org/0000-0002-3794-641X)
- Manman Zhang
- Huiting Mo
- Hanbin Zhang (ORCID: https://orcid.org/0000-0002-0427-0070)
- Yuntian Wu (ORCID: https://orcid.org/0000-0002-3694-0817)
- Yuancheng Huang (ORCID: https://orcid.org/0000-0003-1865-7329)
- Chen Chen (ORCID: https://orcid.org/0000-0003-0000-5920)
- Peiliang Kong
- G. B. Chen
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou First People's Hospital (CN)
- Dongguan People’s Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/11795549251388872
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00